|
|
Prepublished online as a Blood First Edition Paper on January 30, 2003; DOI 10.1182/blood-2002-07-2274.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 36-42
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
Michel Gilliet,
Martin Kleinhans,
Erica Lantelme,
Dirk Schadendorf,
Günter Burg, and
Frank O. Nestle
From the Department of Dermatology, University of Zurich Medical School, Zurich, Switzerland; the Basel Institute for Immunology, Basel, Switzerland; and the Clinical Cooperation Unit for Dermatooncology (DKFZ) at the Klinikum Mannheim, Heidelberg, Germany.
Dendritic cells (DCs) represent the most potent antigen-presenting cells of the immune system capable of initiating primary immune responses to neoantigens. Here we characterize the primary CD4 T-cell immune response to protein keyhole limpet hemocyanin (KLH) in 5 metastatic melanoma patients undergoing a tumor peptide–based dendritic cell vaccination trial. Monocyte-derived dendritic cells displaying a semimature phenotype, as defined by surface markers, were loaded ex vivo with antigen and injected intranodally at weekly intervals for 4 weeks. All patients developed a strong and long-lasting delayed-type hypersensitivity reactivity to KLH, which correlated with the induction of KLH-dependent proliferation of CD4 T cells in vitro. Secondary in vitro stimulation with KLH showed significant increase in interferon- and interleukin-2 (IL-2) but not IL-4, IL-5, nor IL-10 secretion by bulk T cells. On the single-cell level, most TH1 cells among in vitro–generated KLH-specific T-cell lines confirmed the preferential induction of a KLH-specific type 1 T helper immune response. Furthermore, the induction of KLH-specific antibodies of the IgG2 subtype may reflect the induction of a type 1 cytokine profile in vivo after vaccination. Our results indicate that intranodal vaccination with semimature DCs can prime strong, long-lasting CD4 T-cell responses with a TH1-type cytokine profile in cancer patients. (Blood. 2003;102:36-42)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Jasny, M. Eisenblatter, K. Matz-Rensing, K. Tenner-Racz, M. Tenbusch, A. Schrod, C. Stahl-Hennig, V. Moos, T. Schneider, P. Racz, et al.
IL-12-Impaired and IL-12-Secreting Dendritic Cells Produce IL-23 upon CD154 Restimulation
J. Immunol.,
May 15, 2008;
180(10):
6629 - 6639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Meyer-Wentrup, D. Benitez-Ribas, P. J. Tacken, C. J. A. Punt, C. G. Figdor, I. J. M. de Vries, and G. J. Adema
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-{alpha} production
Blood,
April 15, 2008;
111(8):
4245 - 4253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Grover, G. J. Kim, G. Lizee, M. Tschoi, G. Wang, J. R. Wunderlich, S. A. Rosenberg, S. T. Hwang, and P. Hwu
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5801 - 5808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. A. Rayes, A. C. Rawstron, G. J. Morgan, and F. E. Davies
The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells
Blood,
June 15, 2005;
105(12):
4895 - 4896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mazzolini, C. Alfaro, B. Sangro, E. Feijoo, J. Ruiz, A. Benito, I. Tirapu, A. Arina, J. Sola, M. Herraiz, et al.
Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas
J. Clin. Oncol.,
February 10, 2005;
23(5):
999 - 1010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Tosi, R. Valenti, A. Cova, G. Sovena, V. Huber, L. Pilla, F. Arienti, F. Belardelli, G. Parmiani, and L. Rivoltini
Role of Cross-Talk between IFN-{alpha}-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens
J. Immunol.,
May 1, 2004;
172(9):
5363 - 5370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Vonderheide, S. M. Domchek, J. L. Schultze, D. J. George, K. M. Hoar, D.-Y. Chen, K. F. Stephans, K. Masutomi, M. Loda, Z. Xia, et al.
Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes
Clin. Cancer Res.,
February 1, 2004;
10(3):
828 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
